CClinicalTrials.gg
TerminatedNCT02046226Updated Oct 12, 2015Results posted

Dissolved Oxygen Dressing to Improve Chronic Wound Healing After Revascularization for Critical Limb Ischemia

An interventional study of Oxygenesys(TM) Dissolved Oxygen Dressing in Critical Limb Ischemia, sponsored by Halyard Health. Terminated at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2015-10-12.

Sponsored by Halyard Health · Not applicable, Interventional, and Treatment

Why this study was terminated
inability to meet enrollment goals in this subject population
Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

A Prospective, Randomized, Single-center Pilot Study of The OxyGenesys(TM) Dissolved Oxygen Dressing to Improve Chronic Wound Healing after REvascularization for Critical Limb Ischemia.

Read the detailed description

A Prospective, Randomized, controlled pilot study enrolling up to 50 subjects at a singe investigational site in the US. Subjects with atherosclerotic peripheral arteria disease (PAD) presenting with critical limb ischemia (CLI) and one or more non-healing lower extremity arterial insufficiency ulcers who are suitable candidates for revascularization procedures (endovascular or surgical) will be randomized 1:1 to:

  • Wound care with the use of OxyGenesys(TM) Dissolved Oxygen Dressing, or
  • Standard Wound Care procedures

An initial study phase will enroll up to 20 subjects (10 in each arm). Pending results of the initial study phase, the study may continue to enroll until up to 50 subjects (25 in each arm) have been enrolled.

All subjects will be followed clinically and receive wound evaluation at 1, 3, and 6 months.

02

Conditions studied

  • Critical Limb Ischemia

Keywords

  • Critical Limb Ischemia
  • Non Healing Wounds
  • Diabetic Wounds
  • Foot Ulcers
03

In context

Chronic Limb-Threatening Ischemia

343 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 70 are open to participants now.

This study's enrollment of 7 is below the median of 45 across 233 interventional studies indexed under Chronic Limb-Threatening Ischemia.

Browse Chronic Limb-Threatening Ischemia studies →

Lead sponsor

Halyard Health is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male or non-pregnant female >=21 years of age
  • A clinical diagnosis of critical limb ischemia (CLI) with Rutherford classification stage 5
  • One or more chronic ulcers with a presumed etiology of arterial insufficiency and duration >2 weeks. The target ulcer is defined as the highest-grade ulcer (Wagner's classification) at initial evaluation. For wounds with identical grading, the largest wound is the index wound
  • The patient or legally authorized representative is willing to provide informed consent and comply with specified follow-up evaluations
  • Undergoing intervention for infrainguinal or infrapopliteal artery disease (below the femoral artery bifurcation and above the ankle joint)
  • The index procedure resulted in successful revascularization. For endovascular procedures, successful revascularization is defined as complete revascularization of the target ulcer culprit vessels according to the angiosome treatment strategy, with a final percent diameter stenosis >50% and improved distal flow by angiography following the procedure. For surgical procedures, successful revascularization is defined as a patent graft and improved distal flow following the procedure.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following index procedure. Female patients of child-bearing potential must have a negative pregnancy test done within 7 days prior to index procedure.
  • Rutherford classification stage 0,1,2,3,4, or 6
  • Target wound duration \<2 weeks
  • Presence of frank gangrene (Wagner classification grade 4 or 5), major tissue loss (severe/extensive necrosis), or unsalvageable limb (extensive ischemic ulceration beyond the transmetatarsal level anticipated to require major amputation after the index procedure)
  • Previous or planned surgical or interventional procedure within 6 months before or 30 days after the index procedure, or any previous or planned target limb amputation.
  • Active local or systemic infection
  • Patients with ulcers judged by the examining physician to have a primary etiology other than ischemic arterial disease (e.g., venous related, decubitus, or other [goug, pyoderma gangrenosum, necrobiosis lipoidica, vitamin B12 deficiency])
  • Renal failure or chronic kidney disease with estimated glomerular filtration rate (eGFR \<30 ml/min/1.7sm sq. within 30 days of the index procedure or treated with dialysis)
  • Severly decreased cardiac output
  • Uncontrolled hyperglycemia
  • Patients with a known other medical illness or known history of substance abuse that may cause non-compliance with the protocol, confound data interpretation, or is associated with a life expectancy of less than 1 year
  • Patient is currently participating (or has participated in the last 30 days) in a study of any other investigational treatment.
  • Ulcer treatment with normothermic or hyperbaric oxygen therapy, recombinant or autologous growth factor products, or use of enzymatic debridement
  • Concomitant medications such as corticosteroids, immunosuppressive medications, or chemotherapy
  • Acute thrombus in the target limb
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    OxyGenesys(TM) Dissolved Oxygen Dressing

    OxyGenesys(TM) Dissolved Oxygen Dressing

    Device: Oxygenesys(TM) Dissolved Oxygen Dressing

  • No intervention
    Standard Wound Care

    Standard wound care using gauze dressings per institutional standard of care.

Interventions

  • DeviceOxygenesys(TM) Dissolved Oxygen Dressing

    OxyGenesys(TM) Dissolved Oxygen Dressing

06

What researchers measure

Primary outcomes

  1. Rate of Wound Healing

    Percentage reduction in target wound area (length x width).

    Time frame: 3 months

Secondary outcomes

  1. Incidence of Complete Wound Closure

    number of wounds undergoing complete reepithelialization without drainage or dressing requirements, maintained for at least 2 weeks.

    Time frame: 3 months

07

Results

Posted Oct 12, 2015

Participant flow

Participant flow — Overall Study
MilestoneAll Study Participants
Started7
Completed0
Not completed7
Withdrew: Lost to follow-up7

Outcome measures

PrimaryRate of Wound Healing

Percentage reduction in target wound area (length x width).

Time frame:
3 months

No measurements were reported for this outcome.

SecondaryIncidence of Complete Wound Closure

number of wounds undergoing complete reepithelialization without drainage or dressing requirements, maintained for at least 2 weeks.

Time frame:
3 months

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Study Participants———

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All Study Participants
<=18 yearsNA
Between 18 and 65 yearsNA
>=65 yearsNA
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
FemaleNA
MaleNA
08

Study locations

1 site
  • Yale New Haven Hospital
    New Haven, Connecticut 06510, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 12, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02046226
Lead sponsor
Halyard Health
Collaborators
Yale University
Responsible party
Sponsor
First posted
Jan 27, 2014
Start date
Aug 2013
Primary completion
May 2014
Completion
May 2014
Results posted
Oct 12, 2015
Last update
Oct 12, 2015

Study contacts

Carlos Mena-Hurtado, MD
principal investigator · Yale University
David T Curd, MS
study director · Kimberly-Clark Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion